FJY Stock Chart & Stats
€0.02
<€0.01(18.75%)
At close: 4:00 PM EST
€0.02
<€0.01(18.75%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume10.00K
Average Volume (3M)739.00
Market Cap
€3.64M
Enterprise Value€5.85
Total Cash (Recent Filing)€1.71M
Total Debt (Recent Filing)€2.52M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding589,877,800
10 Day Avg. Volume1,968
30 Day Avg. Volume739
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€8.73M
Bulls Say, Bears Say
Bulls Say
2026 Revenue ReboundThe 2026 revenue rebound indicates renewed commercial activity after sharp declines in 2024 and 2025. If maintained, stronger sales can improve operating leverage, support product investment, and provide a more durable foundation for eventual profitability.
Positive Cash FlowPositive operating and free cash flow in the latest year reduces immediate reliance on external funding and supports ongoing operations. Although the record is volatile, this improvement provides a stronger base for managing development and commercial activities.
Narrower Net LossA substantially narrower net loss shows progress toward reducing the gap between revenue and costs. Continued improvement could extend the benefit of the revenue rebound and help the company move toward sustainable profitability, even though it remains loss-making.
Bears Say
Persistent UnprofitabilityPersistent accounting and operating losses indicate that the business model has not yet demonstrated sustainable profitability. This limits internally generated capital, increases dependence on financing, and leaves results vulnerable if revenue growth does not continue.
Weaker Balance SheetA compressed equity base and materially higher leverage reduce the financial cushion available to creditors and shareholders. For a loss-making biotechnology company, this can constrain investment flexibility and increase funding risk during periods of weaker performance.
Volatile Revenue And Cash GenerationSharp revenue fluctuations and inconsistent cash generation make forward planning difficult and weaken confidence in the durability of recent improvements. Cash burn could return if revenue normalizes or costs rise, increasing pressure on the already weaker balance sheet.
Acrux News
FJY FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is €3.64M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 185 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited does not currently pay dividends.
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 589,877,800 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -21.429%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in DE:FJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
DE:FJY Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―